Myriad Genetics (NASDAQ:MYGN – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.03, Briefing.com reports. The business had revenue of $196.60 million for the quarter, compared to analysts’ expectations of $194.80 million. Myriad Genetics had […]
Related Keywords
Canada , Hong Kong , United States , Piper Sandler , Wolfe Research , Tower Research Capital , Wells Fargo Company , Us Bancorp , Jpmorgan Chase Co , Royal Bank , Goldman Sachs Group , Genetics Company Profile , Hong Kong Ltd , Genetics Inc , Myriad Genetics , Get Free Report , Research Capital , Kong Ltd , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily , Nasdaq Mygn , Mygn , Medical , 62855j10 , Earnings ,
vimarsana.com © 2020. All Rights Reserved.